Drug-induced cardiotoxicity is a major problem in drug discovery. Many approaches to efficient drug screening have been developed, including animal testing in vivo and cell testing in vitro. However, due to intrinsic difference between species, animal-based toxicity testing cannot comprehensively determine the potential side effects in subsequent human clinical trials. Furthermore, conventional in vitro assays are costly and labour intensive, and require numerous tests. Therefore, it would be necessary to develop heart-on-a-chips made with advanced materials and soft bioelectronic fabrication techniques that offer fast, efficient, and accurate sensing of cardiac cells' behaviors in vitro. In this review, we introduce two key sensing me...
Pharmaceutical compounds may have cardiotoxic properties, triggering potentially life-threatening ar...
We present an integrated platform comprised of a biomimetic substrate and physiologically aligned hu...
Early and accurate detection of plasma borne cardiac biomarkers is essential for prevention of life ...
As cardiac diseases are one of the main causes of death worldwide, research on better understanding ...
The emerging heart-on-a-chip platforms are promising approaches to establish cardiac cell/tissue mod...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Drug discovery is a long and expensive process, whose efficiency is often limited due to the poor pr...
Drug development continuously faces challenges in efficiently predicting toxicity and verifying effi...
Drug-induced cardiotoxicity is a major barrier to drug development and a main cause of withdrawal of...
Animal models and traditional cell cultures are essential tools for drug development. However, these...
The motions of the heart are regulated by electrophysiological signals, which can be monitored and a...
Abstract There has been considerable interest in developing microsensors integrated within lab-on-a-...
Today’s heart-on-a-chip devices are hoped to be the state-of-the-art cell and tissue characterizing ...
Pharmaceutical compounds may have cardiotoxic properties, triggering potentially life-threatening ar...
We present an integrated platform comprised of a biomimetic substrate and physiologically aligned hu...
Early and accurate detection of plasma borne cardiac biomarkers is essential for prevention of life ...
As cardiac diseases are one of the main causes of death worldwide, research on better understanding ...
The emerging heart-on-a-chip platforms are promising approaches to establish cardiac cell/tissue mod...
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing...
Drug discovery is a long and expensive process, whose efficiency is often limited due to the poor pr...
Drug development continuously faces challenges in efficiently predicting toxicity and verifying effi...
Drug-induced cardiotoxicity is a major barrier to drug development and a main cause of withdrawal of...
Animal models and traditional cell cultures are essential tools for drug development. However, these...
The motions of the heart are regulated by electrophysiological signals, which can be monitored and a...
Abstract There has been considerable interest in developing microsensors integrated within lab-on-a-...
Today’s heart-on-a-chip devices are hoped to be the state-of-the-art cell and tissue characterizing ...
Pharmaceutical compounds may have cardiotoxic properties, triggering potentially life-threatening ar...
We present an integrated platform comprised of a biomimetic substrate and physiologically aligned hu...
Early and accurate detection of plasma borne cardiac biomarkers is essential for prevention of life ...